IDORSIA AG SF-,05/ CH0363463438 /
04.06.2024 17:41:16 | Diff. -0,238 | Volumen | Geld17:41:16 | Brief17:41:16 | Marktkapitalisierung | Dividendenr. | KGV |
---|---|---|---|---|---|---|---|
2,432EUR | -8,91% | - Umsatz: - |
2,432Geld Vol: - | 2,506Brief Vol: - | -EUR | - | - |
dpa-AFX
31.05
GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of ...
dpa-AFX
23.05
GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
dpa-AFX
21.05
GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors
dpa-AFX
21.05
GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company wi...
dpa-AFX
21.05
GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to c...
dpa-AFX
14.05
GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and confer...
dpa-AFX
01.05
GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 20...
dpa-AFX
26.04
GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant ...
dpa-AFX
17.04
GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting
dpa-AFX
20.03
GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endotheli...
dpa-AFX
18.03
GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and develo...
dpa-AFX
28.02
GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboratio...
GlobeNewswire
28.02
Idorsia and Viatris enter into a significant global research and development collaboration
dpa-AFX
10.01
GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustaina...
dpa-AFX
03.11.2023
GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been pres...
GlobeNewswire
03.11.2023
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...
dpa-AFX
24.10.2023
GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unt...
dpa-AFX
23.10.2023
GNW-Adhoc: Idorsia is committed to further the science of sleep with a symposium and poster presenta...
- Erste Seite
- Zurück
- 1
- 2
- 3
- 4
- Weiter
- Letzte Seite